Recombinant human interleukin-2（Shenzhen kexing)

重组人白介素-2 (深圳科兴）

Report date: 2022/02/21 10:42:31

Base Information

Drug NameRecombinant human interleukin-2（Shenzhen kexing)
Drug Alias Name重组人白细胞介素-2（深圳科兴）注射用重组人白介素-2（深圳科兴）悦康仙Recosun
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsAscitesPleural Effusion, MalignantCarcinoma, Renal Cell +[4] 
Global Approved IndicationsAscitesPleural Effusion, MalignantCarcinoma, Renal Cell +[4] 
Approved Indications in ChinaAscitesPleural Effusion, MalignantCarcinoma, Renal Cell +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date1998/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen Kexing Biological Engineering Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Kexing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAscitesPleural Effusion, MalignantCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A